This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huettner, C. Articles by Roggendorf, W. Search for Related Content PubMed PubMed Citation Articles by Huettner, C. Articles by Roggendorf, W.

American Journal of Pathology, Vol 146, 317-322, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas

C Huettner, W Paulus and W Roggendorf
Institute of Pathology, Neuropathology, University of Wurzburg, Germany.

Interleukin 10 (IL-10) was initially discovered on the basis of its ability to suppress cytokine synthesis. Additionally, it can exert immunosuppressive effects on a variety of cell types. Because patients with malignant gliomas present with a general impairment of the immune system, we investigated IL-10 expression in the glioma tissue. Because expression of IL-10 and IL-6 is associated in hematopoietic cells and IL-6 can act as an autocrine growth stimulator for glioblastoma cell lines, we looked in addition for a relationship between IL-10 and IL-6 expression. Using a quantitative reverse transcriptase polymerase chain reaction, IL-10 and IL-6 mRNA levels were determined in 37 glial tumors of different grades including 2 recurrencies, 3 specimens from normal brain tissue, and 3 glioblastoma cell lines. Expression of IL-10 mRNA was demonstrable in all tumors as well as in normal brain. High grade tumors and recurrent cases expressed significantly higher amounts of IL- 10-specific mRNA compared with low grade tumors, whereas 2 of 3 cell lines showed only weak constitutive expression, mRNA for IL-6 was found in 86.5% of all gliomas with a correlation concerning the expression levels for both cytokines in 69% of gliomas. We suggest that IL-10 may contribute to the progression of astrocytomas by suppressing the patient's immune response, whereas IL-6 provides an additional growth advantage.

This article has been cited by other articles:

				E. Zeni, L. Mazzetti, D. Miotto, N. Lo Cascio, P. Maestrelli, P. Querzoli, M. Pedriali, E. De Rosa, L. M. Fabbri, C. E. Mapp, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Eur. Respir. J., October 1, 2007; 30(4): 627 - 632. [Abstract] [Full Text] [PDF]

				J. Tang, P. Flomenberg, L. Harshyne, L. Kenyon, and D. W. Andrews Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells Clin. Cancer Res., July 15, 2005; 11(14): 5292 - 5299. [Abstract] [Full Text] [PDF]

				H. H. Steiner, M. M. Bonsanto, P. Beckhove, M. Brysch, K. Geletneky, R. Ahmadi, R. Schuele-Freyer, P. Kremer, G. Ranaie, D. Matejic, et al. Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical Benefit J. Clin. Oncol., November 1, 2004; 22(21): 4272 - 4281. [Abstract] [Full Text] [PDF]

				J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression Clin. Cancer Res., August 1, 2004; 10(15): 5094 - 5100. [Abstract] [Full Text] [PDF]

				D. A. Caruso, L. M. Orme, A. M. Neale, F. J. Radcliff, G. M. Amor, W. Maixner, P. Downie, T. E. Hassall, M. L.K. Tang, and D. M. Ashley Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer Neuro-oncol, July 1, 2004; 6(3): 236 - 246. [Abstract] [PDF]

				I Y Rosenblum and A D Dayan Carcinogenicity testing of IL-10: principles and practicalities Human and Experimental Toxicology, July 1, 2002; 21(7): 347 - 358. [Abstract] [PDF]

				G. E. Plautz, D. W. Miller, G. H. Barnett, G. H. J. Stevens, S. Maffett, J. Kim, P. A. Cohen, and S. Shu T Cell Adoptive Immunotherapy of Newly Diagnosed Gliomas Clin. Cancer Res., June 1, 2000; 6(6): 2209 - 2218. [Abstract] [Full Text]

				K. Yamazaki, G. Spruill, J. Rhoderick, J. Spielman, N. Savaraj, and E. R. Podack Small Cell Lung Carcinomas Express Shared and Private Tumor Antigens Presented by HLA-A1 or HLA-A2 Cancer Res., September 1, 1999; 59(18): 4642 - 4650. [Abstract] [Full Text] [PDF]

				J.-P. Zou, L. A. Morford, C. Chougnet, A. R. Dix, A. G. Brooks, N. Torres, J. D. Shuman, J. E. Coligan, W. H. Brooks, T. L. Roszman, et al. Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) That Alters Monocyte Cytokine Profile and Surface Markers J. Immunol., April 15, 1999; 162(8): 4882 - 4892. [Abstract] [Full Text] [PDF]

				J. H. Sampson THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif. Neuro-oncol, January 1, 1999; 1(1): 33 - 42. [PDF]